Latest news with #EnvisionHealthcare
Bloomberg
25-06-2025
- Business
- Bloomberg
Envision Healthcare Inks Debt Deal with Lenders Amid Turnaround
Envision Healthcare Corp. agreed to a deal with its lenders that will cut the company's borrowing costs in the midst of a turnaround for the business. The physician staffing firm will refinance its roughly $400 million term loan into a $295 million term loan, according to people familiar who asked not to be identified discussing a private matter. The new loan will be priced at 6.5 percentage points over SOFR at a discount of 99 cents on the dollar, which is cheaper than the original loan, the people added.
Business Wire
25-06-2025
- Business
- Business Wire
Envision Healthcare Strengthens Financial Position With Completion of Key Financing Transactions
NASHVILLE, Tenn.--(BUSINESS WIRE)--Envision Healthcare, a leading national medical group ('Envision' or the 'Company'), announced the successful completion of two significant financing transactions designed to enhance the Company's financial flexibility and long-term stability. These transactions underscore Envision's commitment to building a sustainable future focused on delivering high-quality patient care. Envision has secured a new Term Loan and a new Asset-Based Lending (ABL) Revolving Credit Facility. The new Term Loan refinanced the Company's existing term loan, extending the maturity to 2030, further strengthening Envision Healthcare's balance sheet. These strategic steps position the organization to continue investing in its core infrastructure and services while reducing overall interest expense. 'This is a big step forward for Envision,' said Jason Owen, President and Chief Executive Officer of Envision Healthcare. 'These new financial agreements reflect the confidence our lending partners have in our Company's purpose and long-term strategy. With improved flexibility and reduced debt, we believe we are well-positioned to support our teams and continue delivering compassionate, high-quality care to the communities we serve.' The new capital structure is expected to generate meaningful cost savings, optimize resource allocation and enable continued strategic investments across the organization. The transactions also highlight the support and trust Envision continues to earn from its financial stakeholders. This announcement follows Envision's successful financial restructuring in 2023 to right-size the Company's capital structure. These new financing agreements represent a proactive move to support long-term growth, enhance operational flexibility and solidify the Company's financial foundation. Goldman Sachs Bank USA and Wells Fargo Bank, National Association, served as Joint Lead Arrangers and Bookrunners for the ABL facility, with participation from a syndicate of additional lenders. Sidley Austin LLP served as counsel for Envision Healthcare and Latham and Watkins LLP served as counsel for Goldman Sachs. About Envision Healthcare Envision Healthcare is a leading medical group that delivers physician and advanced practice provider services, primarily in the areas of emergency and hospitalist medicine, anesthesiology, radiology/teleradiology and neonatology. Envision's medical group offers a differentiated suite of clinical solutions on a national scale with a local understanding of our communities, creating value for health systems, payers, providers and patients. For additional information, visit Cautionary Statement Regarding Forward-Looking Statements This press release contains certain forward-looking statements (all statements other than with respect to historical fact) within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby. Lenders and stockholders are cautioned that all forward-looking statements involve known and unknown risks and uncertainties including, without limitation, the Company's ability to comply with the covenants in its term loan agreement and ABL facility and to use the proceeds thereof on growth initiatives. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate. Therefore, there can be no assurance that the forward-looking statements included herein will prove to be accurate. Actual results could differ materially and adversely from those contemplated by any forward-looking statement. In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the Company's objectives and plans will be achieved. The Company undertakes no obligation to release any revisions to any forward-looking statements to reflect events and circumstances occurring after the date hereof or to reflect unanticipated events.
Bloomberg
17-06-2025
- Business
- Bloomberg
Ascension Health Expands Reach With $3.9 Billion Amsurg Deal
Ascension Health has agreed to buy AmSurg, an ambulatory surgery company once part of Envision Healthcare Corp., for about $3.9 billion, according to people with knowledge of the matter. The deal will add more than 250 outpatient surgery centers to Ascension's network in the US, where it is one of the biggest nonprofit health systems, as care moves toward lower-cost settings outside of traditional hospitals.
Bloomberg
30-05-2025
- Business
- Bloomberg
Ascension Health Nears $3.9 Billion Deal for Amsurg Outpatient Centers
Amsurg, the ambulatory surgery company once part of Envision Healthcare, is in advanced talks to sell itself to Ascension Health for about $3.9 billion, according to people with knowledge of the matter. A deal with Ascension could be struck within weeks, said the people, who asked not to be identified discussing confidential information.
Yahoo
29-01-2025
- Business
- Yahoo
Lyndra Therapeutics appoints Adam Sayer new CEO and president
Lyndra Therapeutics has announced the immediate appointment of Adam Sayer as its new president and CEO. Sayer, who will also join the company's board of directors, brings experience from his previous role as chief transformation officer at Envision Healthcare. With an understanding of the healthcare ecosystem, Sayer's expertise in strategy, transformation and payer negotiations is expected to be pivotal in progressing the company's programmes, particularly oral weekly risperidone (LYN-005). This long-acting therapeutic is a key focus for the company as it strives to enhance patient experience by offering less frequent dosing. The pivotal safety trial for LYN-005 is scheduled to begin in the first half of 2025. Adam stated: 'I am excited to join Lyndra at this pivotal moment for the company. Lyndra's LYNX platform technology has demonstrated remarkable potential to transform oral medicine delivery and make a meaningful impact on patient outcomes, and I look forward to leading this talented team as we bring the first-ever long-acting oral medicines to market.' Under the stewardship of Jessica Ballinger, outgoing CEO and president, the company completed a pivotal efficacy study for LYN-005. Lyndra Therapeutics board executive chair and co-founder Amy Schulman stated: 'We are grateful for Jess's contributions and overall dedication to our mission. Now, under Adam's leadership and with his focus on business execution, we are poised to achieve our goals and fundamentally change how oral medicines are delivered.' The company recently entered a strategic partnership with Thermo Fisher Scientific, focusing on commercial manufacturing and clinical research on a global scale. Lyndra's LYNX drug delivery platform is tailored to deliver treatments for a week or more in one oral dose. The platform's flexibility and potential have been showcased through clinical proof-of-concept studies across 25 active pharmaceutical ingredients and five therapeutic areas. "Lyndra Therapeutics appoints Adam Sayer new CEO and president" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
